About the Company
Principia Biopharma, Inc. is a biopharmaceutical company, which engages in designing and developing oral therapies to patients with significant unmet medical needs in immunology and oncology. It operates through Tailored Covalency platform, which enables to develop small molecule inhibitors of enzymes and receptor ligands with potencies and selectivities that rival those of injectable biologics, yet maintain the convenience of a pill. Its product pipeline includes PRN1008, PRN2246, PRN1371, and immunoproteasome inhibitor. The company was founded by Jack Taunton and Richard A. Miller on October 6, 2008 and is headquartered in South San Francisco, CA.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $PRNB News
Sanofi adds BTK inhibitors to pipeline with $3.68bn Principia Biopharma acquisition
Sanofi is to buy Principia Biopharma for up to $3.68 billion, adding a potential multiple sclerosis drug to its pipeline. The French pharma said it will pay $100 per share in cash for San ...
Sanofi’s BTK inhibitor hits phase III thrombocytopenia endpoint
An oral Bruton’s tyrosine kinase (BTK) inhibitor that Sanofi SA acquired in 2020 through its $3.68 billion buyout of Principia Biopharma Inc. is headed toward regulatory filings in the U.S and EU by ...
Dow Futures, Barrick Gold, Sanofi, Principia Biopharma - 5 Things You Must Know Monday
Wall Street is coming off its third straight week of gains; Sanofi to acquire U.S. biotech Principia Biopharma; Warren Buffett builds a position in Barrick Gold. Stock futures pointed higher ...
Sanofi to shutter operations at Peninsula drugmaker it bought less than 3 years ago
Bay Area employees of the former Amunix Pharmaceuticals Inc. in South San Francisco were told last Wednesday about the ...
Rilzabrutinib Plus Low-Dose Steroid Fails Pemphigus Trial
Five authors declared being current or former employees of the funding agencies, while others declared having ties with several sources, including Principia Biopharma Inc. and Sanofi.
Sutro Biopharma Inc STRO
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
GT Biopharma Inc GTBP
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
Plc Gsk's Net Worth
Plc Gsk has an estimated net worth of $9.11 Billion. This is based on reported shares across multiple companies, which include Wave Life Sciences Ltd., CVRx, Inc., Lyell Immunopharma, Inc ...
Q4 2023 Cue Biopharma Inc Earnings Call
Stephen Willey; Analyst; Stifel Financial Corp. Reni Benjamin; Analyst; JMP Securities LLC Operator Greetings, and welcome to the Cue Biopharma Investor Update Call. (Operator Instructions ...
Recap: Principia pounds Metro
Principia (4-8) goes on the road to play Whitfield on Friday at 4:15 p.m. Metro (1-4) plays Hancock at Heine Meine on Friday at 4:30 p.m. The Jr. Billikens need one victory to ensure their first ...
Cue Biopharma Inc (CUE) Q4 2023 Earnings Call Transcript Highlights: Strategic Alliances and ...
Collaboration Revenue: Q4 2023: $1.8 million; Full Year 2023: $5.5 million. Research and Development Expenses: Q4 2023: $10.9 million; Full Year 2023: $40.8 million. General and Administrative ...
Loading the latest forecasts...